PANCREAZE®
Exocrine Pancreatic Insufficiency (EPI)
ApprovedActive
Key Facts
About VIVUS
VIVUS is a commercial-stage biopharmaceutical company with a long history of developing and commercializing small molecule therapies. Its current focus appears to be on its obesity drug QSIVA®/QSYMIA® and the pancreatic enzyme product PANCREAZE®. The company has undergone significant restructuring, emerging in 2020 as a wholly-owned subsidiary of Icahn Enterprises L.P., and is now expanding its commercial footprint, particularly in Europe.
View full company profileTherapeutic Areas
Other Exocrine Pancreatic Insufficiency (EPI) Drugs
| Drug | Company | Phase |
|---|---|---|
| PER301 | Perseo Pharma | Preclinical |